Benzo[1,3]dioxine derivatives and their use as LPAR5 antagonists

US9221784B2 · kind B2 · utility

Assignee

• Sanofi · FR

Inventors

• Marc Nazare · Idstein, DE
• Detlef Kozian · Kelkheim, DE
• Martin Bossart · Frankfurt am Main, DE
• Werngard Czechtizky · Frankfurt, DE
• Andreas Evers · Frankfurt am Main, DE

Key dates

• Filing date: May 16, 2013
• Grant date: Dec 29, 2015
• Expiry date: May 16, 2033

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D413/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to compounds of the formula (I), wherein the residues A, R1 to R5, Z1 and Z2 have the meanings indicated in the claims. The compounds of the formula (I) are valuable pharmacologically active compounds for use in the treatment of diverse disorders, for example cardiovascular disorders like thromboembolic diseases or restenoses. The compounds of the invention are effective antagonists of the platelet LPA receptor LPAR5 (GPR92) and can in general be applied in conditions in which an undesired activation of the platelet LPA receptor LPAR5, the mast cell LPA receptor LPAR5 or the microglia cell LPA receptor LPAR5 is present or for the cure or prevention of which an inhibition of the platelet, mast cell or microglia cell LPA receptor LPAR5 is intended. The invention furthermore relates to processes for the preparation of compounds of the formula (I), their use, in particular as active ingredients in medicaments, and pharmaceutical compositions comprising them.